ESC 365 - Uninterrupted novel anticoagulants as safe alternative of transesophageal echocardiographic screening in patients undergoing ablation for atrial fibrillation

ESC Premium Access

Uninterrupted novel anticoagulants as safe alternative of transesophageal echocardiographic screening in patients undergoing ablation for atrial fibrillation

Session: Poster session 3 - Drug treatment

Topic: Antiarrhythmic drugs

Speaker: Mrs A. Shapieva (Moscow, RU)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Mrs Albina Shapieva

Petrovsky National Research Center of Surgery, Moscow (Russian Federation)

0 follower

24 more presentations in this session

Impact of digoxin use on adverse outcomes in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study in China

Speaker: Miss S. Wu (Beijing, CN)

Rate-control treatment and clinical outcomes in patients with atrial fibrillation and obstructive lung disease

Speaker: Doctor S. You (Seoul, KR)

Efficacy of acute intravenous therapy with potassium, magnesium and metoprolol in recent-onset atrial fibrillation

Speaker: Miss A. Moser (Hamburg, DE)

Postoperative atrial fibrillation in patients with reduced ejection fraction heart failure undergoing cardiac surgery: ranolazine shortens time to conversion when added to amiodarone

Speaker: Professor J. Skoularigis (Larissa, GR)

INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin

Speaker: Doctor P. Oliveira Guimaraes (Durham, US)

Access the full session

Poster session 3 - Drug treatment

Speakers: Mrs A. Shapieva, Miss S. Wu, Doctor S. You, Miss A. Moser, Professor J. Skoularigis...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources